Article ID Journal Published Year Pages File Type
2798904 Diabetes Research and Clinical Practice 2007 9 Pages PDF
Abstract

IntroductionInsulin glulisine (glulisine) was evaluated versus regular human insulin (RHI) in Type 2 diabetes (T2DM) patients.MethodsPatients previously on >6 months’ continuous insulin treatment aged ≥18 years in a randomized, multinational, controlled, open-label, parallel group, 26-week study received twice-daily NPH insulin and either glulisine (0–15 min before breakfast and dinner; n = 448) or RHI (30–45 min before breakfast and dinner; n = 442) at least twice daily.ResultsMean baseline characteristics were similar between groups. There were no differences in baseline to endpoint HbA1c reductions (glulisine: −0.32%; RHI: −0.35%; p = 0.5726), and the non-inferiority of glulisine versus RHI was demonstrated (difference in adjusted mean change 0.03%; 95% CI: −0.07, 0.13). Postprandially, glulisine lowered plasma glucose significantly more versus RHI at 2 h (14.14 mmol/L versus 15.28 mmol/L; p = 0.0025) and excursions at 1 h (3.99 versus 4.59; p = 0.0151) and 2 h (4.87 versus 6.03; p = 0.0002). No between-group differences occurred in the frequencies and monthly rates of all symptomatic hypoglycaemia; nocturnal hypoglycaemia from Month 4 to treatment end was less frequent with glulisine versus RHI (9.1% versus 14.5%; p = 0.029).ConclusionGlulisine was non-inferior to RHI in reducing HbA1c in T2DM. Glulisine demonstrated superior postprandial glucose control and was associated with fewer nocturnal hypoglycaemic episodes, indicating clinical benefits.

Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Endocrinology
Authors
, , ,